CYP19A1 and neoplasm: Unlike ER-positive luminal tumours and HER2-positive tumours, the basal-like subtype typically lacks expression of the molecular targets that confer responsiveness to highly effective targeted therapies such as tamoxifen, aromatase inhibitors, or trastuzumab.